Oculis Holding AG SEC filings OCSAW

Oculis Holding AG has 138 filings in SEC EDGAR's recent list, going back to Nov 7, 2022. Its latest annual report, Form 20-F, was filed on Mar 4, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.

Oculis Holding AG SEC filings
Form Description Filed Period
EFFECT Filing Dec 8, 2025 —
EFFECT Filing Sep 6, 2024 —
CORRESP Letter to the SEC Sep 4, 2024 —
UPLOAD Letter from the SEC Aug 30, 2024 —
EFFECT Filing Apr 3, 2024 —
EFFECT Filing Apr 2, 2024 —
CORRESP Letter to the SEC Apr 1, 2024 —
UPLOAD Letter from the SEC Apr 1, 2024 —
EFFECT Filing May 31, 2023 —
CORRESP Letter to the SEC May 30, 2023 —
CORRESP Letter to the SEC May 30, 2023 —
UPLOAD Letter from the SEC May 17, 2023 —
DRS Filing May 10, 2023 —
EFFECT Filing May 1, 2023 —
CORRESP Letter to the SEC Apr 27, 2023 —
CORRESP Letter to the SEC Apr 20, 2023 —
UPLOAD Letter from the SEC Apr 13, 2023 —
CERT Filing Mar 2, 2023 —
8-A12B Filing Mar 1, 2023 —
SEC STAFF LETTER Filing Feb 14, 2023 —
EFFECT Filing Feb 3, 2023 —
CORRESP Letter to the SEC Feb 2, 2023 —
CORRESP Letter to the SEC Feb 1, 2023 —
UPLOAD Letter from the SEC Jan 31, 2023 —
CORRESP Letter to the SEC Jan 27, 2023 —
UPLOAD Letter from the SEC Jan 12, 2023 —
CORRESP Letter to the SEC Jan 6, 2023 —
UPLOAD Letter from the SEC Dec 20, 2022 —
CORRESP Letter to the SEC Dec 12, 2022 —
SEC STAFF LETTER Filing Dec 2, 2022 —
UPLOAD Letter from the SEC Dec 2, 2022 —

Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
OCS (Nasdaq), OCSAW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Switzerland
Headquarters
Zug, Switzerland
SEC filer status
Large accelerated filer
SEC CIK
1953530

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.